254 related articles for article (PubMed ID: 29681457)
1. The Evolutionary Landscape of Localized Prostate Cancers Drives Clinical Aggression.
Espiritu SMG; Liu LY; Rubanova Y; Bhandari V; Holgersen EM; Szyca LM; Fox NS; Chua MLK; Yamaguchi TN; Heisler LE; Livingstone J; Wintersinger J; Yousif F; Lalonde E; Rouette A; Salcedo A; Houlahan KE; Li CH; Huang V; Fraser M; van der Kwast T; Morris QD; Bristow RG; Boutros PC
Cell; 2018 May; 173(4):1003-1013.e15. PubMed ID: 29681457
[TBL] [Abstract][Full Text] [Related]
2. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.
Hamid AA; Gray KP; Shaw G; MacConaill LE; Evan C; Bernard B; Loda M; Corcoran NM; Van Allen EM; Choudhury AD; Sweeney CJ
Eur Urol; 2019 Jul; 76(1):89-97. PubMed ID: 30553611
[TBL] [Abstract][Full Text] [Related]
3. Quantifying the influence of mutation detection on tumour subclonal reconstruction.
Liu LY; Bhandari V; Salcedo A; Espiritu SMG; Morris QD; Kislinger T; Boutros PC
Nat Commun; 2020 Dec; 11(1):6247. PubMed ID: 33288765
[TBL] [Abstract][Full Text] [Related]
4. Somatic genomic alterations in retinoblastoma beyond RB1 are rare and limited to copy number changes.
Kooi IE; Mol BM; Massink MP; Ameziane N; Meijers-Heijboer H; Dommering CJ; van Mil SE; de Vries Y; van der Hout AH; Kaspers GJ; Moll AC; Te Riele H; Cloos J; Dorsman JC
Sci Rep; 2016 Apr; 6():25264. PubMed ID: 27126562
[TBL] [Abstract][Full Text] [Related]
5. Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5α-reductase Inhibition.
Dutta A; Panja S; Virk RK; Kim JY; Zott R; Cremers S; Golombos DM; Liu D; Mosquera JM; Mostaghel EA; Barbieri CE; Mitrofanova A; Abate-Shen C
Eur Urol; 2017 Oct; 72(4):499-506. PubMed ID: 28385453
[TBL] [Abstract][Full Text] [Related]
6. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
[TBL] [Abstract][Full Text] [Related]
7. mTOR pathway activation is a favorable prognostic factor in human prostate adenocarcinoma.
Stelloo S; Sanders J; Nevedomskaya E; de Jong J; Peters D; van Leenders GJ; Jenster G; Bergman AM; Zwart W
Oncotarget; 2016 May; 7(22):32916-24. PubMed ID: 27096957
[TBL] [Abstract][Full Text] [Related]
8. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence.
Kahl P; Gullotti L; Heukamp LC; Wolf S; Friedrichs N; Vorreuther R; Solleder G; Bastian PJ; Ellinger J; Metzger E; Schüle R; Buettner R
Cancer Res; 2006 Dec; 66(23):11341-7. PubMed ID: 17145880
[TBL] [Abstract][Full Text] [Related]
9. An NKX3.1 binding site polymorphism in the l-plastin promoter leads to differential gene expression in human prostate cancer.
Chen C; Cai Q; He W; Li Z; Zhou F; Liu Z; Zhong G; Chen X; Zhao Y; Dong W; Huang J; Zheng J; Lin T
Int J Cancer; 2016 Jan; 138(1):74-86. PubMed ID: 26148677
[TBL] [Abstract][Full Text] [Related]
10. NKX3.1 haploinsufficiency is prognostic for prostate cancer relapse following surgery or image-guided radiotherapy.
Locke JA; Zafarana G; Ishkanian AS; Milosevic M; Thoms J; Have CL; Malloff CA; Lam WL; Squire JA; Pintilie M; Sykes J; Ramnarine VR; Meng A; Ahmed O; Jurisica I; van der Kwast T; Bristow RG
Clin Cancer Res; 2012 Jan; 18(1):308-16. PubMed ID: 22048240
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of an epithelial plasticity biomarker panel in men with localized prostate cancer.
Armstrong AJ; Healy P; Halabi S; Vollmer R; Lark A; Kemeny G; Ware K; Freedland SJ
Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):40-5. PubMed ID: 26458958
[TBL] [Abstract][Full Text] [Related]
12. A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.
Van Den Eeden SK; Lu R; Zhang N; Quesenberry CP; Shan J; Han JS; Tsiatis AC; Leimpeter AD; Lawrence HJ; Febbo PG; Presti JC
Eur Urol; 2018 Jan; 73(1):129-138. PubMed ID: 28988753
[TBL] [Abstract][Full Text] [Related]
13. Genomic Correlates to the Newly Proposed Grading Prognostic Groups for Prostate Cancer.
Rubin MA; Girelli G; Demichelis F
Eur Urol; 2016 Apr; 69(4):557-560. PubMed ID: 26563871
[TBL] [Abstract][Full Text] [Related]
14. Retrospective study testing next generation sequencing of selected cancer-associated genes in resected prostate cancer.
Lo Iacono M; Buttigliero C; Monica V; Bollito E; Garrou D; Cappia S; Rapa I; Vignani F; Bertaglia V; Fiori C; Papotti M; Volante M; Scagliotti GV; Porpiglia F; Tucci M
Oncotarget; 2016 Mar; 7(12):14394-404. PubMed ID: 26887047
[TBL] [Abstract][Full Text] [Related]
15. Genetic predisposition to early recurrence in clinically localized prostate cancer.
Borque Á; del Amo J; Esteban LM; Ars E; Hernández C; Planas J; Arruza A; Llarena R; Palou J; Herranz F; Raventós CX; Tejedor D; Artieda M; Simon L; Martínez A; Carceller E; Suárez M; Allué M; Sanz G; Morote J
BJU Int; 2013 Apr; 111(4):549-58. PubMed ID: 22759231
[TBL] [Abstract][Full Text] [Related]
16. Validation of Novel Biomarkers for Prostate Cancer Progression by the Combination of Bioinformatics, Clinical and Functional Studies.
Alinezhad S; Väänänen RM; Mattsson J; Li Y; Tallgrén T; Tong Ochoa N; Bjartell A; Åkerfelt M; Taimen P; Boström PJ; Pettersson K; Nees M
PLoS One; 2016; 11(5):e0155901. PubMed ID: 27196083
[TBL] [Abstract][Full Text] [Related]
17. Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker.
Chavan SS; He J; Tytarenko R; Deshpande S; Patel P; Bailey M; Stein CK; Stephens O; Weinhold N; Petty N; Steward D; Rasche L; Bauer M; Ashby C; Peterson E; Ali S; Ross J; Miller VA; Stephens P; Thanendrarajan S; Schinke C; Zangari M; van Rhee F; Barlogie B; Mughal TI; Davies FE; Morgan GJ; Walker BA
Blood Cancer J; 2017 Feb; 7(2):e535. PubMed ID: 28234347
[TBL] [Abstract][Full Text] [Related]
18. Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer.
Bañez LL; Sun L; van Leenders GJ; Wheeler TM; Bangma CH; Freedland SJ; Ittmann MM; Lark AL; Madden JF; Hartman A; Weiss G; Castaños-Vélez E
J Urol; 2010 Jul; 184(1):149-56. PubMed ID: 20478579
[TBL] [Abstract][Full Text] [Related]
19. High BIRC7 Expression Might Be an Independent Prognostic Indicator of Poor Recurrence-Free Survival in Patients With Prostate Cancer.
Yang Y; Sun P; Xu W; Xia W
Technol Cancer Res Treat; 2018 Jan; 17():1533033818809694. PubMed ID: 30376767
[TBL] [Abstract][Full Text] [Related]
20. Clonality of localized and metastatic prostate cancer.
Boutros PC; Fraser M; van der Kwast T; Bristow RG
Curr Opin Urol; 2016 May; 26(3):219-24. PubMed ID: 26885716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
